Table 2.
Cessation rates at end-points.
|
End of treatmenta |
Six months |
Twelve months |
||||
|---|---|---|---|---|---|---|
| Placebo (n = 135) | Nicotine (n = 134) | Placebo (n = 135) | Nicotine (n = 134) | Placebo (n = 135) | Nicotine (n = 134) | |
| Prolongedb | 20.0% | 21.6% | 14.1% | 13.4% | 11.9% | 12.7% |
| Seven-day point prevalentc | 25.9% | 25.4% | 19.3% | 14.2% | 14.8% | 20.1% |
P > 0.05 for all comparisons (between nicotine and placebo arms).
a
End of treatment analysis conducted at day 46 post-quit day.
b
Defined as no self-reported smoking and carbon monoxide <10 p.p.m. following a grace period of two weeks after the scheduled quit day.
c
Defined as no self-reported smoking for the seven days preceding the follow-up visit and carbon monoxide <10 p.p.m.